Eisai Seeks To Launch ‘Blockbuster' Cancer Drug In Singapore
This article was originally published in PharmAsia News
Executive Summary
Eisai said it has chosen Singapore to apply for its first approval in the Asia-Pacific region for its E7389 (synthetic halichondrin B), a blockbuster candidate for treating breast cancer. Eisai, which also plans to apply for approval at home, in Europe and the United States early next year, has the compound in trials for treating non-small-cell lung and prostate cancers as well as breast cancer. Eisai created the compound that controls the proliferation of cancer cells. (Click here for more - a subscription may be required
Eisai said it has chosen Singapore to apply for its first approval in the Asia-Pacific region for its E7389 (synthetic halichondrin B), a blockbuster candidate for treating breast cancer. Eisai, which also plans to apply for approval at home, in Europe and the United States early next year, has the compound in trials for treating non-small-cell lung and prostate cancers as well as breast cancer. Eisai created the compound that controls the proliferation of cancer cells. (Click here for more - a subscription may be required) "Eisai Seeks Cancer Drug Approval In Singapore" - Nikkei (Japan) (8/27/09) |